GPNMB Monoclonal Antibody (CTSREVL), eFluor™ 660, eBioscience™, Invitrogen™

Description

• This CTSREVL MAb recognizes human GPNMB also known as Osteoactivin, DC-HIL and HGFIN
• This type-1 transmembrane glycoprotein was described independently as a bone development factor, tumor related molecule, neurokinin, and immune regulator
• Expressed on macrophages and dendritic cells, GPNMB is a ligand for proteoglycan Syndecan-4 (SD-4), which is found on T cells and is known to inhibit their activation and proliferation
• Hence, surface expression of GPNMB by myeloid cells may be indicative of their tolerogenic properties
• Various cancers express GPNMB, and it is suspected to help in immune evasion
• Treatment with IL-10 and various immunosuppressive drugs (e.g., dexamethasone) upregulate GPNMB on macrophages and dendritic cells
• GPNMB may also be secreted
• The CTSREVL antibody will work on paraformaldehyde-fixed cells
• The protein encoded by this gene is a type I transmembrane glycoprotein which shows homology to the pMEL17 precursor, a melanocyte-specific protein
• GPNMB shows expression in the lowly metastatic human melanoma cell lines and xenografts but does not show expression in the highly metastatic cell lines
• GPNMB may be involved in growth delay and reduction of metastatic potential
• Two transcript variants encoding different isoforms have been found for this gene.